201 results about "Disease activity" patented technology

The invention discloses a Crohn disease focus automatic segmentation and activity evaluation system based on deep learning, which belongs to the field of medical artificial intelligence and comprises a data preprocessing unit, a focus automatic segmentation unit, a radiomics feature extraction unit, a feature screening and dimension reduction unit and an activity classification unit. According to the method, an nnU-Net deep learning segmentation model is combined with image omics feature extraction, multi-stage feature screening and machine learning classification technologies, so that full-process automation from CTE image preprocessing, focus automatic segmentation, feature extraction and screening to activity classification is realized. The system can efficiently and accurately segment the focus of Crohn's disease, automatically assesses the disease activity based on the screened key radiomics characteristics, significantly improves the consistency, objectivity and efficiency of diagnosis, and is suitable for clinical auxiliary diagnosis and scientific research analysis.

According to the borborygmus recognition method and device, the electronic equipment and the storage medium, the borborygmus signal is acquired, the signal is recognized based on the preset borborygmus recognition model, the borborygmus characteristics can be efficiently and accurately analyzed, and therefore a scientific basis is provided for evaluation of the activity range and the lesion range of colitis diseases. According to the method, the diagnostic efficiency and accuracy are improved, through non-invasive borborygmus signal analysis, complexity of traditional endoscopy and discomfort of a patient are avoided, and meanwhile the diagnostic accuracy is improved; and secondly, dynamic monitoring of disease activity is realized, the activity and lesion range of colitis can be evaluated in real time by continuously collecting and identifying borborygmus signals, and dynamic illness state data support is provided for doctors.

A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

The invention discloses a composition containing probiotics and fusion polypeptide and application of the composition in treatment of intestinal inflammatory diseases. The composition is prepared from lactobacillus plantarum (Lactobacillus plantarum CCFM8661) and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the composition. The fusion polypeptide can be used for directly inhibiting the growth of pathogenic bacteria and neutralizing toxins by enhancing the intestinal colonization capability of probiotics, so that the triple synergistic effect of bacteriostasis, repair and immunoregulation is realized. Experiments show that the composition significantly reduces the disease activity index in a DSS-induced mouse colitis model, recovers the colon length, and inhibits serum inflammatory factors IL-6 and TNF-alpha. In addition, the survival rate of the freeze-dried microcapsule preparation in simulated gastric juice is gt; the colon targeted release characteristic is realized. The invention provides an efficient and stable new treatment strategy for intestinal inflammatory diseases.

The invention relates to a system for evaluating the severity of an ulcerative colitis endoscope, and belongs to the technical field of medical systems. The system comprises a data acquisition module, a label calibration module, an ulcerative colitis endoscope severity evaluation model construction module, an ulcerative colitis endoscope severity evaluation model training module, an ulcerative colitis endoscope severity evaluation module and a second data acquisition module. A histological biopsy scoring and processing module; and a data processing and control module. The system provided by the invention can objectively evaluate the endoscopic disease activity of ulcerative colitis in real time and predict histological alleviation, can more accurately guide the formulation of a clinical treatment scheme, and is easy to popularize and apply.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

The present invention discloses a rheumatoid arthritis activity grading device based on multimodal data, which mainly includes: an image preprocessing module for converting multiple joint images of a case into image features; an extraction module for extracting all joint image features using TransformerD; an optimized image representation module for obtaining lesion classification predictions of corresponding images and disease grading predictions of the entire image, and calculating a first cross-entropy loss with the corresponding lesion label; an other modality feature extraction module for extracting and enhancing other modality features using MLP; a feature fusion module for interacting and fusing the above-mentioned modality features using TransformerP to obtain disease grading predictions of multimodal data, and calculating a second cross-entropy loss with the true grading label; a loss function optimization module for training a disease activity grading prediction network; a disease grading prediction module for outputting the disease activity of the case from the grading prediction network given the joint images and other modality data of the case.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.

The invention relates to the technical field of biological medicine, and provides application of TRIM69 in preparation of a kit for auxiliary diagnosis of systemic lupus erythematosus. The kit assists in diagnosing systemic lupus erythematosus by detecting the TRIM69 level. Through the mRNA expression quantity of the TRIM69 and the expression quantity and / or concentration of the protein, the auxiliary diagnosis of the systemic lupus erythematosus is realized, and the TRIM69 as a biomarker has important values in the aspects of auxiliary diagnosis, disease activity monitoring, prognosis evaluation, diagnosis efficiency improvement and the like. Not only can a doctor be helped to recognize a high-risk patient earlier, but also a basis can be provided for individualized treatment, so that the long-term prognosis of the systemic lupus erythematosus patient is improved.

This paper discusses a strain of Bifidobacterium animalis subsp. lactis B7 and its composition and applications, belonging to the field of microbial technology. The specific strain is Bifidobacterium animalis subsp. lactis B7. Bifidobacterium animalis subsp. lactis Bifidobacterium lactis subspecies B7 was deposited at the China Center for Type Culture Collection on April 19, 2024, with accession number CCTCC NO: M2024734. This invention also discloses the application of the B7 fermentation composition in the preparation of drugs for the prevention and treatment of ulcerative colitis, constipation, and constipation-predominant ulcerative colitis. This animal bifidobacterium lactis subspecies B7 produces high levels of short-chain fatty acids and indolepropionic acid, utilizes sulforaphane to generate sulforaphane, increases intestinal peristalsis, effectively alleviates the disease activity index (DAI) and weight loss caused by ulcerative colitis or inflammatory bowel disease, significantly reduces colonic damage in mice, protects the mucosal layer, has anti-inflammatory effects, inhibits pathogens, and improves intestinal barrier function.

The application discloses application of a product for detecting metabolite levels in serum in preparation of a preparation for diagnosing systemic lupus erythematosus (SLE) and SLE patients with different organ involvement phenotypes and a reagent. The application first uses specific serum biomarkers to assist in screening SLE, SLE with different disease activity and SLE patients with different organ phenotypes, including only kidney involvement systemic lupus erythematosus (KI), only skin involvement systemic lupus erythematosus (SI), only blood system involvement systemic lupus erythematosus (BI) and multi-system involvement systemic lupus erythematosus (MI), thereby opening up a new way for the diagnosis of the field and helping to more accurately diagnose and evaluate the disease progression of SLE. The blood specimen required is small, easy to carry out and has a good application prospect.

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.

The invention discloses an anti-tumor composition of irinotecan and liquorice extract or liquorice total flavonoids and a metabonomics detection method of the anti-tumor composition of irinotecan and the liquorice extract or the liquorice total flavonoids. The traditional Chinese medicine composition has an adjusting effect on various enteritis indexes such as body weight, disease activity index score, colon length and reduction of inflammatory factors caused by irinotecan, and has an obvious effect of reducing intestinal toxic and side effects of irinotecan. The invention develops a rapid and efficient UPLC-TQ-MS / MS (ultra performance liquid chromatography-tandem mass spectrometry / mass spectrometry) method capable of synchronously detecting. According to the method, the tissue distribution condition of irinotecan and main metabolites thereof in a mouse body can be detected and quantified with high sensitivity, and the influence of liquorice total flavonoids and liquorice total extracts on the metabolic process and distribution characteristics of irinotecan and metabolites thereof is evaluated; not only can the possible effect of the liquorice in the process of reducing irinotecan be revealed, but also a theoretical basis can be provided for optimization of a medicine compatibility scheme.

Disclosed herein are methods of treating ALS in a subject by administering to the subject a therapeutically effective amount of a composition comprising, for example, EV derived from nerve cells, such as neural progenitor cells. The EVs may be administered distally or peripherally to the CNS such that these EVs cross the blood-brain barrier and exert their therapeutic function in the CNS. The methods may reduce inflammation (e.g., NLRP3 inflammatory pathway signaling), reduce disease activity or progression, and / or improve motor or neurological performance, signs or symptoms associated with ALS, or survival in an ALS subject as compared to a control ALS subject. Also provided are methods of inhibiting necroptosis in a cell by contacting the cell with a therapeutically effective amount of a composition comprising EV.

The invention discloses application of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor in preparation of a medicine for treating leucoderma, and belongs to the technical field of preparation of medicines for treating leucoderma. Through targeted inhibition of ACLY activity or specific knockout of ACLY in CD8 + T cells, abnormal activation of ACLY and secretion of killing effector molecules (Granzyme B, IFN-gamma, Perforin and the like) are inhibited, and infiltration of the CD8 + T cells to skin lesion parts is reduced, so that melanocytes are protected from immune injury, and the progress of vitiligo is blocked. The application is based on the abnormally high expression of ACLY in CD8 + T cells of vitiligo patients and the close association with disease activity, and a brand new targeted treatment thought and a medicine research and development direction are provided for vitiligo.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

The present disclosure relates to methods of identifying a subject with high or low Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), wherein the subject is known to have Systemic Lupus Erythematosus (SLE), and wherein a subject with a high SLEDAI can be treated and a subject with a low SLEDAI can reduce treatment relative to that before the low SLEDAI determination. The methods herein involve detecting the presence of an antibody binding at least one biomarker selected from Ro52Ex4, Ro52Ex3-4, Ro52γCT, and / or Ro52Nt in a sample using routine techniques known in the art.

The invention discloses a dynamic prediction method for a rheumatoid arthritis patient based on multi-modal data fusion and deep learning, and the method is characterized in that a cross-modal attention fusion module is adopted, and the module does not simply splice all features, but learns the mutual dependency relationship between different modal features, and is used for predicting the dynamic prediction of the rheumatoid arthritis patient. Generating an enhanced feature vector capable of representing the synergistic effect; then, the enhanced feature vector and each original modal feature are sent into a gating fusion unit together to adaptively screen and integrate the most critical information for the current prediction task to form a comprehensive'patient current state snapshot '; and finally, inputting a series of state snapshots arranged according to a time sequence into an upper-layer time sequence LSTM model, thereby realizing dynamic prediction of a future disease activity trajectory and a recurrence risk of the patient. According to the method, through a refined fusion strategy and time sequence dynamic deep modeling, the prediction accuracy and interpretability are remarkably improved.

The invention relates to an application of a trichina succinic acid coenzyme A ligase beta-like protein SUCLA-beta. The invention identifies a trichina recombinant protein SUCLA-beta which can be used for preventing or treating colitis. A mouse colitis model is successfully copied, it is proved that the protein can improve intestinal inflammation caused by TNBS, the disease activity indexes of mice treated by the trichina recombinant protein SUCLA-beta in a treatment group or a prevention group are reduced, intestinal injury and inflammation are relieved, the disease activity indexes are gradually reduced along with dosage increase, and the intestinal injury and inflammation are relieved. Intestinal injury and inflammatory symptoms are gradually relieved, and the trichina recombinant protein SUCLA-beta can relieve inflammatory response by adjusting the proportion of Th1 / Th2 / Th17 / Treg cells. The trichina recombinant protein SUCLA-beta has a relatively good application prospect in the aspect of preventing or treating colitis.

The application discloses an application of Bacteroides intestinalis in preventing and / or treating ulcerative colitis and belongs to the field of biopharmacy. The application claims the use of Bacteroides intestinalis in preparing a medicine or a composition for preventing and / or treating ulcerative colitis. It is found that Bacteroides intestinalis can significantly inhibit the weight loss of a mouse model of ulcerative colitis, reduce a disease activity index, repair colon tissue damage, and down-regulate the expression level of a proinflammatory factor of the organism, and thus has a clear preventive and / or therapeutic effect on ulcerative colitis and has a good clinical transformation application prospect. Therefore, the Bacteroides intestinalis has a prospect of being developed into a medicine or a composition for preventing and / or treating ulcerative colitis.

The invention belongs to the field of biological medicine, and particularly relates to application of soluble B7-H5 in preparation of a Crohn disease detection reagent. According to the invention, the level of soluble B7-H5 (sB7-H5) in serum of a patient suffering from Crohn's disease (CD) is deeply analyzed by using an ELISA (Enzyme-Linked Immunosorbent Assay) technology. Studies find that sB7-H5 in serum of a CD patient is remarkably and highly expressed and is positively correlated with a disease activity index (CDAI). Further experimental verification shows that blocking of B7-H5 can promote polarization of inflammatory macrophages. Based on the discoveries, the invention provides the application of the serum B7-H5 as the molecular marker of the Crohn's disease to development of products for detection, prognosis or treatment of the Crohn's disease. The molecular marker can be in a soluble B7-H5 gene or protein form. The invention also shows that the B7-H5 can be used as a potential target for developing the medicine for preventing and treating the Crohn disease, and has important clinical application value.

This application discloses the application of dasabuvir as a TRPV4 inhibitor in improving diseases caused by increased TRPV4 expression or enhanced activity, particularly ulcerative colitis. Specifically, it relates to the biomedical field. Dasabuvir is a novel TRPV4 inhibitor that can improve symptoms in a DSS-induced mouse ulcerative colitis model and is suitable for use in TRPV4 inhibitor drugs and ulcerative colitis drugs. In HEK-293 cells overexpressing TRPV4, dasabuvir can dose-dependently inhibit the increase in intracellular calcium ion concentration induced by the TRPV4-specific agonist GSK1016790A within a concentration range of 0.03-30 μM, with an IC50 concentration of [missing information]. 50 At a concentration of 0.27 μM, Dasabuvir is a highly active TRPV4 inhibitor. In a DSS-induced ulcerative colitis model, Dasabuvir can improve weight loss, reduce the disease activity index, alleviate colonic shortening, reduce histopathological changes, and inhibit the expression of inflammatory factors, thus improving ulcerative colitis.

The invention discloses a saliva biomarker and application thereof in rheumatoid arthritis disease activity assessment, and relates to the technical field of biomarkers. The saliva biomarker is one of the secretion amount of saliva extracellular vesicles and the expression level of porphyromonas gingivalis peptidyl arginine deiminase in the saliva extracellular vesicles. Peptidyl arginine deiminase exists in extracellular vesicles secreted by porphyromonas gingivalis in saliva, and in a patient with rheumatoid arthritis, the secretion amount of the extracellular vesicles in the saliva is remarkably increased and is in positive correlation with disease activity; the expression level of porphyromonas gingivalis peptidyl arginine deiminase in saliva extracellular vesicles is remarkably improved and is in positive correlation with disease activity. According to the invention, real noninvasive and high-compliance detection is realized based on a saliva sample, and large-scale screening and long-term management can be realized.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The invention belongs to the field of biological medicines, and particularly discloses an identification method of honeysuckle flower polysaccharide and application of the honeysuckle flower polysaccharide in preparation of medicines for preventing or treating inflammatory bowel diseases. A DSS solution is used for inducing a mouse inflammatory bowel disease model, honeysuckle polysaccharide FLP is used for gavage treatment, and mouse weight, disease activity indexes, colorectal tissue pathological structures, spleen pathological structures, HE staining, intestinal microbial structures, intestinal metabolite spectrums and the like are detected and analyzed. Results show that the honeysuckle flower polysaccharide can delay inflammatory bowel diseases of model animals in an oral administration manner, and has the characteristics of high targeting property, convenience in administration and the like. Good application prospects are realized in the aspect of treating the inflammatory bowel disease.

The invention provides lactobacillus plantarum S7-12, fermented vegetables and application of the lactobacillus plantarum S7-12 and the fermented vegetables, and belongs to the technical field of microbial fermentation, the lactobacillus plantarum S7-12 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66578. The plant lactobacillus S7-12 has relatively strong growth ability, acid production ability, acid resistance and salt resistance, and fermented vegetables prepared from the plant lactobacillus S7-12 can be used for relieving weight loss and colon shortening caused by inflammatory bowel diseases, reducing disease activity indexes and visceral organ indexes, relieving intestinal mucosa structural damage, relieving oxidative stress injury of colon, and improving the immunity of the vegetables. The release of proinflammatory factors in serum and colon is reduced, the secretion of anti-inflammatory factors is improved, the expression quantity of colon tight junction protein is increased, the TLR4 pathway is activated, and the colon barrier function is improved; the method can be used for preparing health-care foods or medicines, and has a wide application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to chlorogenic acid temperature-sensitive sol, a preparation method and application thereof, chlorogenic acid gel and application thereof. According to the chlorogenic acid temperature-sensitive sol provided by the invention, the chlorogenic acid with anti-inflammatory activity is combined with a temperature-sensitive material for the first time to construct a temperature response type in-situ gel delivery system. The chlorogenic acid temperature-sensitive sol provided by the invention is in a flowable sol state at room temperature, and is convenient for administration in a liquid form through an injector or an enema device; when the temperature-sensitive material is in contact with a human body cavity mucous membrane, the temperature-sensitive material triggers sol-gel phase change through an intermolecular hydrophobic effect to form semi-solid three-dimensional mesh gel which is tightly adhered to the surface of the mucous membrane, so that positioned enrichment and long-acting slow release of a medicine in a focus area are realized, the symptoms of ulcerative colitis are relieved, and the disease activity index is reduced; the colon length shortening and the pathological injury of colon tissues are improved, the technical defects of non-uniform distribution, short enema retention time and the like of the traditional suppository are overcome, and the colon suppository has clinical application potential.

The application discloses application of a reagent for detecting a biomarker in preparation of a product for predicting ulcerative colitis disease activity or a product for diagnosing ulcerative colitis disease, and relates to the technical field of serological markers of inflammatory bowel disease. The serum CD105 of a UC patient is significantly higher than that of a healthy control group, and CD105 has a very high effect of diagnosing ulcerative colitis disease, and CD105 can distinguish disease activity from remission. Therefore, the application provides a novel serum marker which is convenient to sample, has good repeatability and can objectively reflect the colon mucosa inflammation load, and is expected to provide more accurate marker selection for UC disease activity prediction and UC diagnosis.

The present disclosure relates to a method, device, and program for providing a service to determine the activity level of a disease on the basis of responses to question information designed to evaluate the activity level of a disease that a user possesses, thereby allowing for quick intervention by a doctor according to the determined activity level. The method includes: collecting symptom information for various diseases; generating multiple pieces of question information and a list of answers for evaluating the activity level for each of the various diseases on the basis of the collected symptom information; acquiring information about the disease that a user possesses; providing the user with question information and an answer list corresponding to the disease that the user possesses; and determining the activity level of the disease that the user possesses on the basis of the answers to the question information obtained from the user.